Cometriq (cabozantinib) — CareFirst (Caremark)

Initial criteria

• The disease is not amenable to radioactive iodine (RAI) therapy
• The disease has progressed after treatment with lenvatinib or sorafenib

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months